Long-Term Impact of Hepatitis C Virus Eradication on Liver Stiffness in Egyptian Patients

Table 1

Demographic and baseline data.

n = 655	Mean ± SD, n (%)
Demographics
Age (years)	51.44 ± 10.45
Sex, n (%)
Male	478 (73%)
Female	177 (27%)
BMI	29.13 ± 2.80
Diabetes mellitus	180 (27.4)
Hypertension	87 (13.3)
Laboratory data
Albumin (gm/dL)	4.08 ± 0.54
Bilirubin (mg/dL)	0.83 ± 0.45
INR	1.11 ± 0.13
ALT (IU/l)	65.10 ± 51.89
AST (IU/l)	88.98 ± 39.60
Hb (gm/dl)	14.08 ± 1.77
WBCs (×10³/mm³)	6.35 ± 2.12
Platelets (×10³/mm³)	178.17 ± 71.63
HCV RNA (IU/ml)	1526115.6 ± 2650113
Fasting blood glucose (mg/dL)	112 ± 55
Baseline LSM (kPa)	18.4 ± 14.45
Noncirrhotics	8.29 ± 2.31
Cirrhotics	29.66 ± 14.25
State of fibrosis according to LSM
F0-1	116 (17.7%)
F2	117 (17.9%)
F3	109 (16.6%)
F4 (cirrhosis)	313 (47.8%)
Child–Pugh class A	208 (66.4%)
Child–Pugh class B	105 (33.6%)
Child–Pugh class C	0 (0%)
Treatment regimen, n (%)
SOF + RBV	302 (46.1%)
SOF + SIM	28 (4.3%)
SOF + DCV ± RBV	325 (49.6%)

BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Hb, hemoglobin; WBCs, white blood count; HCV RNA, hepatitis C virus ribonucleic acid; INR, international normalized ratio; kPa, kilo Pascal; LSM, liver stiffness measurement; SOF, sofosbuvir; RBV, ribavirin; SIM, simiprevir; DCV, daclatasvir.